FDA Brief

Warning letters Drugs

FDA warning letter to

Cholrem Pty Ltd dba Cholrem and Cholrem Pharmaceuticals

High riskIssued Jul 9, 2024Posted Jul 16, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Cholrem over selling unapproved RemChol enema products with claims to treat atherosclerosis and reverse heart disease.

What happened

In May 2024, FDA reviewed Cholrem’s websites and social media pages and found the company offering RemChol, RemChol Saver Set, RemChol Starter Pack, and RemChol Ultra Set for sale in the United States. The pages claimed these products treat atherosclerosis, reverse heart disease, reduce plaque, lower cholesterol, and provide other disease benefits. FDA concluded the products are unapproved new drugs.

What FDA found

  1. FDA treated RemChol and Cavadex/Cavadextrin as drugs because the websites and social media said they diagnose, cure, mitigate, treat, or prevent disease or affect body structure or function.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA said the products are not generally recognized as safe and effective for those uses, so they are new drugs.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. FDA said no approved application is in effect for the products, so selling them in U.S. interstate commerce violates the FD&C Act.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks Cholrem to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If correction cannot be completed in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • sellers of enema or cyclodextrin products with disease claims
  • companies that market online and through social media in the U.S.
  • quality and regulatory teams reviewing consumer product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk